I n 1988 20 new drugs were approved by the federal Food and Drug Administration (FDA). Only two will be first used by Americans; the remaining 18 drugs have been approved and used in foreign countries. In fact, one new drug is the only approved nonionic contrast agent developed and manufactured by a U.S. company.
The occupational health nurse may not be exposed to all 20 new entities, since several are hospital oriented or indicated for diagnostic purposes only (see Table) . However, most of the new drugs may be used by employees in the workplace.
This article will provide pertinent and timely information on the newest antihistamine, sunscreen, beta blockers, antifungal agents, calcium channel blockers, imaging agents, antibiotics, peptomimetic agent, reducing/complexing agent, sclerosing agent, antineoplastic, prostaglandin, dopamine agonist, and nonsteroidal antiinflammatory drug (NSAID).
ASTEMIZOLE
Astemizole (Hismanal) is a long acting, nonsedating antihistamine indicated for the treatment ofchronic allergic conditions such as allergic rhinitis, allergic conjunctivitis, chronic urticaria, and angioedema. However, astemizole has a delayed onset of action (up to several days) and cannot be used effectively for acute allergic conditions. Dosage of astemizole is 10 mg once daily for adults and 5 mg (one-half tablet) for children 6 to 12 years of age. The dosage for children under 6 years of age has not been established in the U.S.; however, 0.2 mg/kg/day is used in Europe.
With the long onset of action the effects of astemizole may not be seen until the fifth day of therapy. In persons with recurrent allergic conditions, treatment should be started 1to 2 weeks before the expected onset of symptoms. Another alternative is to give a conventional antihistamine also until the astemizole takes effect.
Sedation and central nervous system depression are uncommon. Increased appetite and weight gain may occur due to a direct effect by astemizole on the hypothalamic satiety center.
Employees should be told to take this medication on an empty stomach because food can decrease effectiveness. Also, employees should be aware that it may take several days for astemizole to take effect. Until astemizole begins its therapeutic effect, the occupational health nurse might consider recommending an over-the-counter "pure" antihistamine to the employee with the understanding the in a few days it will no longer be necessary (Drug News Weekly, Jan 9, 1989; Kistenansky, 1988) .
BUTYL METHOXYDI-BENZOYLMETHANE
Butyl methoxydibenzoylmethane (Photoplex sunscreen lotion), also known as Parsdol1789, is a sunscreen compound which absorbs 65% more ultraviolet A rays than the commonly used sunscreen oxybenzone. It also contains padirnate-O,
The drug is licensed from the Swiss firm Givaudan and has been used in Europe for about 7 years. It originally appeared in the U.S. as an ingredient in a line of cosmetics. However, the FDA considered it an unapproved new drug which required testing.
Many job classifications have direct, long-term exposure to sunlight which can have deleterious effects on the skin. Proper use of this product by employees may prevent or decrease skin disorders (Abramowicz, 1988a) .
CARTEOLOL
Carteolol (Cartrol), a once daily beta blocker used for treating hypertension, is a long acting, nonselective, beta-adrenergic blocking agent which lowers pulse rate less significantly than other beta blockers. Presently, carteolol is not being marketed (Drug News l*ekly, Jan 9, 1989) .
CEFOTIAM HCI
Cefotiam hydrochloride (Ceradon) is a third generation cephalosporin developed by the Japanese pharmaceutical firm Takeda. It has been licensed to the Princeton, Nj-based firm, Besselaar Laboratories.
This broad spectrum antibiotic is useful in ampicillin-resistant infections and given only by LV. or LM. injection (Kastrup, 1989) .
DICLOFENAC SODIUM
First approved in Japan in 1974, diclofenac sodium (Voltaren) is a NSAID with antipyretic and analgesic activity. The drug's inhibition of prostaglandin (PG) synthesis is probably responsible for its antiinflammatory property.
Because diclofenac undergoes "first-pass" metabolism in the liver, only about one-half of the absorbed dose is available for use by the body. And, although the extent of drug absorption is not influenced by administration with food, it may be delayed by 1 to 4Yz hours, and sometimes as long as 10 hours. The pharmacokinetics of this drug do not appear to be influenced by age or by renal or hepatic status. Diclofenac is approved for rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. Con-traindications are known allergy to the drug, asthma, urticaria, and other allergy-like manifestations as a result of therapy with aspirin, diclofenac, or other NSAIDs. Serious anaphylactic reactions, some fatal, have occurred in sensitive persons.
Drug interactions can occur with concurrent use of aspirin (displaced from binding proteins), digoxin, or methotrexate (increased serum levels), diuretics (hindered action), lithium (increased serum levels), and cyclosporine (enhanced nephrotoxicity). The drug should not be taken during pregnancy and it should not be used by nursing mothers, since it is excreted in human milk.
The most common side effects, as with all NSAIDs, are abdominal pain or cramps, constipation, diarrhea, indigestion, and nausea. Also seen are headache and dizziness. Clients undergoing long-term treatment with diclofenac should also have hepatic transaminase levels measured about every 6 weeks.
Dosage is 100 to 200 mg/day in 2 or 3 divided doses. It is available in strengths of 25, SO, and 75 mg. The occupational health nurse should caution employees not to crush or break diclofenac tablets and to be on the lookout for recurrent gastrointestinal symptoms which may indicate gastrointestinal ulceration or liver toxicity (Abramowicz, 1988b; Kastrup, 1989; Skoutakis, 1988; .
ETHANOLAMINE OLEATE
Ethanolamine oleate (Ethamolin) is a sclerosing agent, introduced by virtue of the federal law governing tax credit incentives for research and marketing of so-called "orphan drugs." It is indicated for internal bleeding from esophageal varices. These varices are usually associated with portal hypertension stemming from hepatic disease (e.g., cirrhosis) and secondary to bulimia. The drug has been used in the United Kingdom and Canada.
Usual dosage of ethanolamine is 1.5 to 5 ml per varix, with a maximum dose per treatment session not to exceed 20 ml. The solution, which is injectable only, comes as 2 ml ampules in packs of 10, at a concentration of 5%. After injection, the drug disappears from the injection site within 5 minutes. The sclerosing effect of the drug appears to be delayed.
The occupational health nurse should warn female employees against using this drug during pregnancy. Use of this drug for sclerosing varicosities of the leg has not been supported by adequately controlled clinical trials.
At least three deaths from anaphylactic shock have been reported. Therefore, it is wise to keep this possibility in mind when administering this drug and to have a 0.25 mg dose of epinephrine on hand (0.25 ml of a 1:1000I. V. solution). As with any sclerosing drug, long-term use can lead to esophageal necrosis. Cases of fatal aspiration pneumonia in elderly c1i-ents have been reported. The latter seems to be procedure related rather than drug related.
Adverse reactions include pleural effusion/infiltration, esophageal ulcer, pyrexia, retrosternal pain, esophageal stricture, and pneumonia. Reported infrequent reactions are esophagitis, tearing of the esophagus, necrosis, periesophageal abscess, and perforation.
The drug vial should be inspected for particulate matter and discoloration before use (Kastrup, 1989) .
, a paramagnetic substance which exhibits a "magnetic moment" in a magnetic field, is administered by injection before magnetic resonance imaging. It will build up in areas of irregular vascularity or where the blood-brain barrier has been disrupted. This category would include neoplasms, abscesses, and subacute infarcts. It will not highlight normal cells or pinpoint lesions, such as cysts and old scars.
Gadopenterate has no known contraindications or interaction potentials. It is rated Category C for use in pregnant patients, ie, it is to be used only if the benefit justifies the potential risk to the fetus. It is not known if the drug is secreted in human milk, and so should be used cautiously in nursing mothers. Safety and efficacy in pediatric use has not been established.
Even though occupational health nurses are not intimately involved with this procedure, they may be asked by employees or others about magnetic resonance imaging and what medications will be administered at the time of testing. Should this situation arise, they can give appropriate information regarding gadopentetate dimeglumine and its testing significance.
The most common side effect of gadopenretate is headache, which is fleeting, and mild to moderate in severity. Other side effects include nausea, localized pain, and vomiting.
Persons with hemoglobin blood disorders (e.g., sickle cell anemia) are at risk to develop vaso-occlusive problems. Hypotension has also been noted.
Dosage is 0.2 ml/kg given at a rate no greater than 10 mllminute, with a maximum dose of 20 ml. Injections should be followed by a 5 ml normal saline flush to remove any residual trace of the drug. Any unused portion should be discarded immediately. Magnetic resonance imaging should be completed within an hour of injection. The drug is available as a 20 ml single dose vial containing 469.01 mgt ml of gadopenretate (FDC Reports, January 9, 1989).
IFOSFAMIDE
Ifosfamide (lfex) is a chemotherapeutic agent discovered in 1965 and approved by the FDA in 1988. It is used with two other chemotherapeutic agents, vinblastine and cisplatin, to treat refractory testicular carcinoma. Ifosfamide is effective; however, it produces a highly toxic metabolite which causes bladder irritation and hemorrhagic cystitis.
Ifosfamide is activated by microsomal liver enzymes, then metabolized to form the active metabolite which interferes with DNA replication. It has been tested and proven effective in other carcinomas (e.g., soft tissue sarcomas and lymphomas), but has not been approved for their treatment.
This drug is indicated as a third line therapy for clients who have not responded to first line (cisplatin, etoposide V-16, and bleomycin) or second line (surgical removal of diseased tissue) therapies, or who have relapsed after remission. The recommended dosage is 1.2 gm per square meter per day, I. V., for 5 consecu tive days, repeated every 3 weeks.
To prevent urotoxicity, the uroprotective drug, mesna (discussed later), should be administered with ifosfamide and the client should be hydrated with two liters of fluid per day. Other adverse reactions may occur, including myelosuppression, alopecia, nausea and vomiting, hematuria, and central nervous sys-tem toxicity (Zalupski, 1988) .
IOVERSOL
Ioversol (Optiray) is a new imaging agent by Mallinckrodt which will be marketed abroad sometime in 1989 (Kastrup, 1989) .
MESNA
Mesna (Mesnex) has only one indication: to prevent urotoxicity secondary to ifosfamide therapy. Mesna binds with the urotoxic metabolite produced by ifosfamide and prevents its toxic effect.
This drug is indicated as a prophylactic agent in reducing the incidence of hemorrhagic cystitis. The total daily dose is 60% of the total daily dose of ifosfamide. Mesna is divided into three doses to be given at the time of ifosfamide administration, and 4 and 8 hours afterward.
Adverse reactions include a bad taste in the mouth, soft stools, diarrhea, nausea, and vomiting.
MISOPROSTOL
Misoprostol (Cytotec) is a synthetic prostaglandin approved for the prevention ofgastric ulcers in persons taking NSAIDs. Misoprostol's action inhibits gastric acid secretion, and it has a mucosal protective property which further prevents irritation of the stomach lining. This drug is rapidly absorbed and inhibition of gastric acid secretion is usually seen within 30 minutes of administration, and lasts for at least 3 hours. Although misoprostol has been shown effective in preventing gastric ulcers, it does not prevent bleeding and perforation of existing ulcers. It is not effective in treating duodenal ulcers and does not prevent gastrointestinal pain caused by NSAIDs.
The recommended dosage is 200 f.Lg, four times daily (after meals and at bedtime). Misoprostol should not be given to pregnant women or women of childbearing age because of its ability to produce uterine contractions which may result in uterine bleeding and miscarriage.
The most common adverse reactions of misoprostol are 'gastrointestinal in nature: diarrhea, abdomi-nal pain, nausea, flatulence, dyspepsia, vomiting, and constipation. Other adverse effects include headache, uterine bleeding, and cramping.
It is important to warn female employees of the risks to pregnancy while taking misoprostol because of its ability to cause miscarriage and severe uterine bleeding. If the employee does become pregnant, she should be told to stop taking misoprostol immediately and to contact her health care provider. This drug is controversial, since it can be used as an abortifacient.
Employees taking this medication may experience diarrhea some time after the second week of therapy. This adverse reaction usually subsides within a week. Advise the employee to continue taking the drug, but to take it after meals and at bedtime; this will help reduce the severity of the diarrhea (Drug News Weekly, January 2, 1989; Kastrup, 1989; Monk, 1987) .
NAFTIDINE HCI 1%
Naftidine HCI (Naftin) is the first member in a new class of antifungals. The drug seems to inhibit a substance necessary for maintenance of fungus cell membrane integrity.
Naftidine is very active against several dermatophytes, but has very little activity against yeasts such as Candido albicans, It is indicated for treatment of tinea corporis (body ringworm) and tinea cruris (jock itch). The drug appears to work faster than the imidazoles.
The only known contraindication is allergy to the drug or inactive ingredients of the cream base. No interaction potential is known. When the topical dose was increased by 150 times and given orally to rats and rabbits, naftidine did not appear to impair fertility or cause injury to the fetuses. Adequate studies have not been performed in pregnant women (as such studies would be unethical); therefore, the drug should be used only if clearly needed. Common side effects include stinging and burning, dryness, erythema, and local irritation.
Kuhar, Kuhar
Naftidine is to be applied topically and gently massaged into the affected and surrounding skin area(s) morning and evening for 7 to 14 days after symptoms abate. Treatment should be halted in the event of irritation or sensitivity. Naftidine is available as a cream in 2, 15, and 30 gm size tubes.
Employees should be reminded to wash their hands after using naftidine, and that the product should not contact the eyes, nose, mouth, and mucous membranes. Occlusive dressings are not recommended unless otherwise directed by a health care provider. Employees should advise the prescribing provider if no progress occurs after 4 weeks of therapy (Abramowicz, 1988c) .
NICARDIPINE
Nicardipine (Cardene) is a calcium channel blocker used for treating chronic stable angina and hypertension. This drug blocks specific ion channels of cell membranes in cardiac and smooth muscle. When this occurs, calcium cannot pass through the membranes to generate an action potential and subsequent contraction of the muscle. The result of this action is relaxed peripheral and myocardial arterial vascular tone. Nicardipine's antianginal effect is most likely due to the drug's ability to increase myocardial oxygen supply and decrease myocardial oxygen demand.
The recommended starting dose is 20 mg three times daily on an empty stomach. This dose can be adjusted to 40 mg three times daily, depending on the employee's therapeutic response.
The most frequently reported adverse reactions are headache, dizziness, skin flushing, palpitations, and edema. Other side effects include nausea, fatigue, skin rash, and increased severity of unstable angina pectoris.
The occupational health nurse should instruct the employee to take nicardipine 1 hour before or 2 hours after meals. Food delays absorption, which could alter the drug's effec-tiveness. The employee should also be told the importance of taking this medication regularly, since missed doses can decrease effectiveness (Hasegawa, 1988; .
NIMODIPINE
Nimodipine (Nimotop) is a calcium channel blocker approved and developed for the treatment of subarachnoid hemorrhage. This drug will not be marketed until late 1989 (Drug News Hi'ekry, January 9, 1989) .
NIZATIDINE
Nizatidine (Axid), the fourth H-2 histamine receptor blocker to be approved in the U.S., is a reversible and competitive inhibitor of histamine release, especially in parietal cells. Once administered, this drug can thwart nocturnal gastric acid secretion for up to 12 hours. Inhibition will occur even after acid secretion has been stimulated by food, caffeine, betazole, and pentagastrin. This drug shares several of the characteristics of rantidine (Zantac) and famotidine (Pepcid).
Nizatidine has a short half life of 1 to 2 hours and has fast clearance from the plasma. Both, however, are greatly extended in persons with moderate to severe renal impairment, with half life increasing to 3.5 to 11 hours. The dosage must be decreased accordingly.
Administration with food increases the extent of drug absorption and maximum concentration by about 10%. Nizatidine has no significant influence on prolactin release or any anti-androgenic effect.
Nizatidine is indicated for use up to 8 weeks in the treatment of active duodenal ulcers. It is also indicated for maintenance therapy after healing has occurred, seen within 4 weeks of initiation of therapy.
A clinically insignificant reaction occurs in co-administration of the drug with antacids containing aluminum and magnesium salts. There may be theoretically delayed or decreased absorption of the drug. Nizatidine has been shown to raise salicylate levels when given with high doses of aspirin. Nizatidine does not inhibit the cytochrome P-450 enzyme system (metabolizing complex enzyme) and it can be given with drugs primarily metabolized in the liver (e.g., diazepam, chlordiazepoxide, lorazepam, warfarin, metoprolol, and theophylline). Nizatidine is contraindicated in those allergic to the compound or to other H-2 inhibitors.
In animal studies, two rabbit fetuses exhibited abnormalities after I. V. administration of nizatidine. The drug should be administered with extreme caution in pregnant women and only if potential benefits justify potential risks to the fetus. The drug is believed to be excreted in human milk and should be used cautiously, if at all, by nursing mothers. Safety and effectiveness in children has not been determined.
Nizatidine is available in 150 and 300 mg capsules (Abramowicz, 1988d) .
'OCTREOTIDE ACETATE
Octreotide acetate (Sandostatin) is a synthetic hormone given for control of symptoms caused by metastatic carcinoid and vasoactive intestinal peptide secreting tumors. This compound suppresses secretion of serotonin, insulin, glucagon, pancreatic peptide, and growth hormone. Secretion of gastrin, vasoactive intestinal peptide, secretin, and motilin (gut peptides) are also inhibited. Octreotides halflife is 1.5 hours and its duration of action can be up to 12 hours.
Octreotide does not improve the malignancies, but it can quell the symptoms. It may be administered along with other medications to alleviate severe symptoms.
Adequate, well controlled studies have not been performed in pregnant women and it is not known if octreotide is excreted in human milk. Therefore, it should be used only if clearly indicated.
Adverse reactions include nausea, pain at injection site, diarrhea, abdominal pain, loose stools, vertigo, fatigue, hyperglycemia, edema, weakness, and wheals or erythema at the injection site. Octreotide has also been linked to the formation of gall stones.
Dosage of octreotide starts at 50 fJ-g subcutaneous one to two times daily. If tolerated, the dosage can be slowly raised to a range of 100to 600 fJ-g daily depending on the type of tumor.
It may be an adjunctive role of the occupational health nurse to educate and/or support the employees and their caretakers in administering the drug (Rosenberg, 1988; Gaginella, 1988) .
OXICONAZOLE NITRATE
Oxiconazole nitrate (Oxistat) is a broad spectrum imidazole-type antifungal formulated as a 1%topical vanishing cream. It is indicated for the treatment of tinea corporis (body ringworm), tinea cruris (jock itch), and tinea pedis (athlete's foot).
This cream should be applied sparingly to the affected areas after the skin is washed and patted dry. It should be rubbed in thoroughly and the hands should be washed immediately after application. Oxiconazole should be applied to the affected area(s) two to three times daily.
Systemic absorption of oxiconazole seems to be low with currently no evidence of harm to the fetus. The drug should be used in pregnancy only if benefits clearly outweigh any risks to the fetus. This is a standard caution when teratogenic effects of a drug are poorly understood or unknown. Oxiconazole is excreted in breast milk, so nursing mothers should be cautioned about using the drug.
The drug is for external use only and employees should avoid introduction of it into the eyes. Oxiconazole should be applied to the affected area for at least 2 to 4 weeks for full effectiveness.
Common adverse reactions are itching (locally), irritation, erythema, maceration, and fissuring (Kastrup, 1989) .
PERGOLIDE MESVLATE
Pergolide mesylate (permax) is a long-acting dopamine agonist approved as an adjunct to levodopacarbidopa therapy in Parkinson's disease. It is the second such drug in this category, the first being bromocriptine (Parlodel). Its pharmacologic profile and adverse effects are similar to bromocriptine.
Pergolide provides additional therapeutic benefits for employees who are currently well maintained on optimal dosages of levodopa and those who are beginning to develop tolerance to levodopa. Although pergolide enhances the therapeutic effects of levodopa alone, it is even more effective when given with the levodopa-carbidopa combination (Sinemet), Undesirable adverse effects of akinesia-rigidity and tremorswhich may be caused either by levodopa or the disease itself, are reduced by pergolide.
Pergolide was approved by the FDA in December 1988 and should be on the market shortly (Kastrup, 1989) .
TECHNETIUM TC 99M
EXAMETAZINE Technetium TC 99M Exametazine (Ceretec) is an injectable imaging agent due for release on the market in the near future (Kastrup, 1989; Van Sonnenberg, 1988) .
TIOPRONIN
Tiopronin (Thiola) is used to treat the hereditary condition, homozygous cystinuria, which affects an estimated 10,000 Americans. Those with homozygous cystinuria excrete large amounts of the amino acid lysine in the urine because the renal tubules are incapable of reabsorbing normal quantities. This results in kidney stone formation.
Tiopronin, a reducing and complexing agent, takes part in a thiodisulfide exchange with the amino acid cystine. The final product is a water-soluble mixed disulfide. This interaction prevents cystine kidney stone formation in severe homozygous cystinuria.
Tiopronin should be used when more than 500 mg per day of urinary cystine is detected and only after conservative treatments, such as dietary changes, fluid intake, and therapy with d-penicillamine (Cuprimine) have been unsuccessful. Normal dosage is 1 to 2 gm/day in three divided doses, administered 1 hour before or 2 hours after meals.
This drug should not be given to pregnant women unless cystinuria is so severe that the potential benefits definitely outweigh the potential hazards to the fetus. Tiopronin is excreted in breast milk and could harm a nursing infant. For this reason, it should not be given to nursing mothers. Others who should not use the drug include those who have previously suffered agranulocytosis, aplastic anemia, thrombocytopenia secondary to tiopronin use, or to children under 9 years of age.
A lupus-like reaction may occur in which case, tiopronin therapy may have to be discontinued. Other possible side effects are fever, joint pain, swollen glands, rash, dulled taste sensation, gastrointestinal upset, dermatologic effects, and allergic reactions. Hematologic, renal, pulmonary, and neurologic problems may also result.
The occupational health nurse should assess the employee if nondrug therapies have been attempted prior to initiating tiopronin therapy. The employee should be informed that it is essential to drink at least 10, 10 oz glasses of fluids daily. Employees who perspire heavily, work in heat related and/or high activity positions, or who experience diarrhea should drink even greater amounts of fluids (Kastrup, 1989) .
CONCLUSION
This review of the new drugs approved in 1988in the U.S. provides pertinent information to the occupational health nurse concerning the drugs' indications, actions, and effects. The occupational health nurse plays a major role in the employees' health status. One component of this role is assisting and supporting employees' medication compliance efforts. With current information on FDA-approved drugs, the occupational health nurse can be more effective in this counseling.
